Biophysical Insights into Implications of PEG-400 on the α-Crystallin Structure: Multispectroscopic and Microscopic Approach.
Journal
ACS omega
ISSN: 2470-1343
Titre abrégé: ACS Omega
Pays: United States
ID NLM: 101691658
Informations de publication
Date de publication:
04 Aug 2020
04 Aug 2020
Historique:
received:
05
06
2020
accepted:
09
07
2020
entrez:
11
8
2020
pubmed:
11
8
2020
medline:
11
8
2020
Statut:
epublish
Résumé
Aggregation and precipitation of α-crystallin play a vital role in the cataract development. This study was targeted to delineate the effect of PEG-400 on the structural integrity of α-crystallin employing a multispectroscopic and microscopic approach. Intrinsic fluorescence and UV-vis spectroscopy suggested alterations in the tertiary structure of α-crystallin, namely global transition of native α-crystallin to a non-native form in the presence of PEG-400. Circular dichroism spectroscopy suggested secondary structural transition in a native conformation of α-crystallin in the presence of PEG-400. Loss in the native conformation of α-crystallin is implicated in cataract developments, thus highlighting the clinical significance of this work. Further, a significant increase in ANS fluorescence of PEG-400-incubated α-crystallin (7 days) suggested this non-native form to be molten globule (MG)-like state. Increased Thioflavin T fluorescence (ThT) and congo red (CR) absorbance along with transmission electron microscopy (TEM) confirmed the formation of the aggregates of α-crystallin after prolonged incubation with PEG-400. Insights into PEG-400-induced structural alterations can provide a platform to search for new therapeutic molecules that can combat α-crystallin-directed eye diseases.
Identifiants
pubmed: 32775924
doi: 10.1021/acsomega.0c02648
pmc: PMC7409245
doi:
Types de publication
Journal Article
Langues
eng
Pagination
19210-19216Informations de copyright
Copyright © 2020 American Chemical Society.
Déclaration de conflit d'intérêts
The authors declare no competing financial interest.
Références
Curr Pharm Biotechnol. 2019;20(12):1028-1036
pubmed: 31364512
J Phys Chem B. 2008 Dec 11;112(49):15893-902
pubmed: 19367903
Biochim Biophys Acta. 2008 Jun;1784(6):946-52
pubmed: 18452722
Pharm Res. 2008 Jul;25(7):1487-99
pubmed: 18172579
EMBO J. 1997 Jan 15;16(2):221-9
pubmed: 9029143
J Biol Chem. 2001 Sep 7;276(36):33755-61
pubmed: 11447233
Biochem J. 1960 Aug;76:381-8
pubmed: 13837240
Proc Natl Acad Sci U S A. 1982 Apr;79(7):2360-4
pubmed: 6285380
EMBO J. 1997 Feb 3;16(3):659-71
pubmed: 9034347
J Ocul Pharmacol Ther. 2016 Mar;32(2):97-101
pubmed: 26540613
Biochim Biophys Acta. 2009 Oct;1790(10):1095-108
pubmed: 19463898
Biochemistry. 2020 Feb 4;59(4):341-342
pubmed: 31944100
Biochim Biophys Acta. 2016 Jan;1860(1 Pt B):252-7
pubmed: 25840354
PLoS One. 2013;8(1):e54061
pubmed: 23342075
Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10449-53
pubmed: 1438232
Protein Sci. 1995 Aug;4(8):1553-62
pubmed: 8520481
Trends Biochem Sci. 2007 Sep;32(9):407-14
pubmed: 17764955
Proc Natl Acad Sci U S A. 1991 May 1;88(9):3652-6
pubmed: 2023914
J Biol Chem. 1993 Jan 25;268(3):1517-20
pubmed: 8093612
Biophys Chem. 1988 Dec;32(2-3):173-85
pubmed: 3251567
J Fluoresc. 2014 Sep;24(5):1423-31
pubmed: 25011697
Int J Biol Macromol. 2019 Apr 1;126:1288-1294
pubmed: 30586590
J Biol Chem. 2004 Jan 30;279(5):3413-9
pubmed: 14615485
Recent Pat Drug Deliv Formul. 2012 Aug;6(2):107-48
pubmed: 22436026
J Biomol Struct Dyn. 2019 Mar;37(4):857-862
pubmed: 29475407
J Biol Chem. 1992 Nov 15;267(32):23337-41
pubmed: 1429679
Eur Biophys J. 2016 Sep;45(6):523-34
pubmed: 27017355
IUBMB Life. 2016 Feb;68(2):156-66
pubmed: 26748578
Arch Biochem Biophys. 2009 Jul 15;487(2):115-22
pubmed: 19467220
Curr Opin Ophthalmol. 1998 Feb;9(1):10-3
pubmed: 10178625
Sci Rep. 2017 Aug 25;7(1):9470
pubmed: 28842631